JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB125189

Anti-RNF31/HOIP antibody

2

(2 Reviews)

|

(12 Publications)

Knockout Tested Rabbit Polyclonal RNF31/HOIP antibody. Suitable for IP, WB and reacts with Human samples. Cited in 12 publications. Immunogen corresponding to Synthetic Peptide within Human RNF31 aa 1000 to C-terminus.

View Alternative Names

ZIBRA, RNF31, E3 ubiquitin-protein ligase RNF31, HOIL-1-interacting protein, RING finger protein 31, RING-type E3 ubiquitin transferase RNF31, Zinc in-between-RING-finger ubiquitin-associated domain protein, HOIP

4 Images
Immunoprecipitation - Anti-RNF31/HOIP antibody (AB125189)
  • IP

Supplier Data

Immunoprecipitation - Anti-RNF31/HOIP antibody (AB125189)

Detection of human RNF31/HOIP by western blot of immunoprecipitates. Samples : Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies : Affinity purified rabbit anti-RNF31/HOIP antibody ab125189 used for IP at 6 μg per reaction. RNF31/HOIP was also immunoprecipitated by a previous lot of this antibody. For blotting immunoprecipitated RNF31/HOIP, ab125189 was used at 1 μg/mL. Detection : Chemiluminescence with an exposure time of 3 minutes.

All lanes:

Immunoprecipitation - Anti-RNF31/HOIP antibody (ab125189)

Predicted band size: 120 kDa

false

Western blot - Anti-RNF31/HOIP antibody (AB125189)
  • WB

Lab

Western blot - Anti-RNF31/HOIP antibody (AB125189)

Western blot : Anti-RNF31 antibody (ab125189) staining at 1/3000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab125189 was shown to bind specifically to RNF31. A band was observed at 130-140 kDa in wild-type A549 cell lysates with no signal observed at this size in RNF31 knockout cell line. To generate this image, wild-type and RNF31 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-RNF31/HOIP antibody (ab125189) at 1/3000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

RNF31 knockout A549 cell lysate at 20 µg

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

HepG2 cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

false

Western blot - Anti-RNF31/HOIP antibody (AB125189)
  • WB

Lab

Western blot - Anti-RNF31/HOIP antibody (AB125189)

Western blot : Anti-RNF31 antibody (ab125189) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab125189 was shown to bind specifically to RNF31. A band was observed at 130 kDa in wild-type A549 cell lysates with no signal observed at this size in RNF31 knockout cell line. To generate this image, wild-type and RNF31 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-RNF31/HOIP antibody (ab125189) at 1/1000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

RNF31 knockout A549 cell lysate at 20 µg

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

HepG2 cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 120 kDa

Observed band size: 130 kDa

false

Western blot - Anti-RNF31/HOIP antibody (AB125189)
  • WB

Unknown

Western blot - Anti-RNF31/HOIP antibody (AB125189)

All lanes:

Western blot - Anti-RNF31/HOIP antibody (ab125189) at 0.4 µg/mL

Lane 1:

HeLa whole cell lysate at 50 µg

Lane 2:

HeLa whole cell lysate at 15 µg

Lane 3:

293T whole cell lysate at 50 µg

Lane 4:

Jurkat whole cell lysate at 50 µg

Predicted band size: 120 kDa

true

Exposure time: 3min

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IP

applications

Immunogen

Synthetic Peptide within Human RNF31 aa 1000 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q96EP0

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p></p>" }, "Chimpanzee": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Elephant": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Gorilla": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Orangutan": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rabbit": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rhesus monkey": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 - 8 Preservative: 0.09% Sodium azide Constituents: 99% Tris citrate/phosphate
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RNF31 also known as HOIP (HOIL-1 Interacting Protein) is a large protein with a molecular weight of around 119 kDa. It is a part of the ubiquitin-proteasome system and functions mechanically as a E3 ubiquitin ligase. RNF31 forms the catalytic component of the Linear Ubiquitin Chain Assembly Complex (LUBAC). Expression of RNF31 occurs in many tissues with notable levels in immune cells and the testes. The protein features a RING-in-between-RING (RBR) motif structure that is critical for its ligase activity.
Biological function summary

RNF31/HOIP plays an important role in immune response regulation. It functions as part of the LUBAC complex alongside SHARPIN and RBCK1 (also known as HOIL-1L) which together catalyze the linear ubiquitination of substrates. These modifications regulate NF-kB signaling which is an important pathway involved in immune and inflammatory responses. RNF31's ubiquitin ligase activity adds linear ubiquitin chains to target proteins influencing their stability and function therefore impacting the immune cell function and survival.

Pathways

RNF31/HOIP integrates into the NF-kB and the apoptosis pathways. In the NF-kB pathway it acts as a regulator of cytokine production and cell survival. RNF31 achieves this through modification of NEMO (NF-kB essential modulator) an important protein in this pathway. In apoptosis regulation linear ubiquitination by RNF31 modulates the activity of proteins such as caspases preventing inappropriate cell death during immune responses. This helps to maintain balance between survival and death signals in cells allowing for proper immune function.

RNF31/HOIP has implications in inflammatory diseases and certain cancers. Dysregulation of LUBAC components including HOIP has been linked with chronic inflammatory conditions like rheumatoid arthritis where inappropriate NF-kB activation occurs. Furthermore aberrations in RNF31 activity have associations with tumorigenesis where its altered signaling pathways can lead to uncontrolled cell proliferation. In these contexts proteins such as A20 may interact with RNF31 affecting the regulation of NF-kB signaling therefore influencing disease progression.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

E3 ubiquitin-protein ligase component of the LUBAC complex which conjugates linear ('Met-1'-linked) polyubiquitin chains to substrates and plays a key role in NF-kappa-B activation and regulation of inflammation (PubMed : 17006537, PubMed : 19136968, PubMed : 20005846, PubMed : 21455173, PubMed : 21455180, PubMed : 21455181, PubMed : 22863777, PubMed : 28189684, PubMed : 28481331). LUBAC conjugates linear polyubiquitin to IKBKG and RIPK1 and is involved in activation of the canonical NF-kappa-B and the JNK signaling pathways (PubMed : 17006537, PubMed : 19136968, PubMed : 20005846, PubMed : 21455173, PubMed : 21455180, PubMed : 21455181, PubMed : 22863777, PubMed : 28189684). Linear ubiquitination mediated by the LUBAC complex interferes with TNF-induced cell death and thereby prevents inflammation (PubMed : 21455173, PubMed : 28189684). LUBAC is recruited to the TNF-R1 signaling complex (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and possibly other components contributing to the stability of the complex (PubMed : 20005846, PubMed : 27458237). The LUBAC complex is also involved in innate immunity by conjugating linear polyubiquitin chains at the surface of bacteria invading the cytosol to form the ubiquitin coat surrounding bacteria (PubMed : 28481331, PubMed : 34012115). LUBAC is not able to initiate formation of the bacterial ubiquitin coat, and can only promote formation of linear polyubiquitins on pre-existing ubiquitin (PubMed : 28481331). Recruited to the surface of bacteria by RNF213, which initiates the bacterial ubiquitin coat (PubMed : 34012115). The bacterial ubiquitin coat acts as an 'eat-me' signal for xenophagy and promotes NF-kappa-B activation (PubMed : 28481331, PubMed : 34012115). Together with OTULIN, the LUBAC complex regulates the canonical Wnt signaling during angiogenesis (PubMed : 23708998). RNF31 is required for linear ubiquitination of BCL10, thereby promoting TCR-induced NF-kappa-B activation (PubMed : 27777308). Binds polyubiquitin of different linkage types (PubMed : 23708998).
See full target information RNF31

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 15:2974 PubMed38582895

2024

Systematic HOIP interactome profiling reveals critical roles of linear ubiquitination in tissue homeostasis.

Applications

Unspecified application

Species

Unspecified reactive species

Yesheng Fu,Lei Li,Xin Zhang,Zhikang Deng,Ying Wu,Wenzhe Chen,Yuchen Liu,Shan He,Jian Wang,Yuping Xie,Zhiwei Tu,Yadi Lyu,Yange Wei,Shujie Wang,Chun-Ping Cui,Cui Hua Liu,Lingqiang Zhang

Disease models & mechanisms 16: PubMed37589075

2023

An interaction between OTULIN and SCRIB uncovers roles for linear ubiquitination in planar cell polarity.

Applications

Unspecified application

Species

Unspecified reactive species

Stephanie M Almeida,Sofiia Ivantsiv,Rieko Niibori,Wade H Dunham,Brooke A Green,Liang Zhao,Anne-Claude Gingras,Sabine P Cordes

The FEBS journal 290:4224-4237 PubMed36779231

2023

Linear ubiquitination improves NFAT1 protein stability and facilitates NFAT1 signalling in Kawasaki disease.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Miao,Guanghui Qian,Renxia Zhang,Yukang Yuan,Yibo Zuo,Yueyue Ding,Xuan Li,Yunjia Tang,Hui Zheng,Haitao Lv

Journal of experimental & clinical cancer research : CR 41:364 PubMed36581998

2022

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Huijie Yang,Min Xue,Peng Su,Yan Zhou,Xin Li,Zhongbo Li,Yan Xia,Chenmiao Zhang,Mingxi Fu,Xiuxia Zheng,Guosheng Luo,Tian Wei,Xinxing Wang,Yinlu Ding,Jian Zhu,Ting Zhuang

Oncology letters 24:394 PubMed36276481

2022

Identification and molecular analysis of RNF31 Q622H germline polymorphism.

Applications

Unspecified application

Species

Unspecified reactive species

Seshiru Nakazawa,Ryo Mamiya,Reika Kawabata-Iwakawa,Daisuke Oikawa,Kyoichi Kaira,Fuminori Tokunaga,Sumihito Nobusawa,Yusuke Sato,Atsushi Sasaki,Toshiki Yajima,Ken Shirabe

Cells 11: PubMed35954242

2022

Suppression of Linear Ubiquitination Ameliorates Cytoplasmic Aggregation of Truncated TDP-43.

Applications

Unspecified application

Species

Unspecified reactive species

Qiang Zhang,Seigo Terawaki,Daisuke Oikawa,Yoshinori Okina,Yoshinosuke Usuki,Hidefumi Ito,Fuminori Tokunaga

Frontiers in immunology 12:635475 PubMed33815386

2021

Crosstalk Between NDP52 and LUBAC in Innate Immune Responses, Cell Death, and Xenophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Hirohisa Miyashita,Daisuke Oikawa,Seigo Terawaki,Daijiro Kabata,Ayumi Shintani,Fuminori Tokunaga

Frontiers in immunology 11:601926 PubMed33329596

2020

Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-κB Activation Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Daisuke Oikawa,Naoya Hatanaka,Takashi Suzuki,Fuminori Tokunaga

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 34:12751-12767 PubMed32738097

2020

Deubiquitylase UCHL3 regulates bi-orientation and segregation of chromosomes during mitosis.

Applications

Unspecified application

Species

Unspecified reactive species

Katerina Jerabkova,Yongrong Liao,Charlotte Kleiss,Sadek Fournane,Matej Durik,Arantxa Agote-Arán,Laurent Brino,Radislav Sedlacek,Izabela Sumara

Communications biology 3:163 PubMed32246052

2020

Molecular bases for HOIPINs-mediated inhibition of LUBAC and innate immune responses.

Applications

Unspecified application

Species

Unspecified reactive species

Daisuke Oikawa,Yusuke Sato,Fumiaki Ohtake,Keidai Komakura,Kazuki Hanada,Koji Sugawara,Seigo Terawaki,Yukari Mizukami,Hoang T Phuong,Kiyosei Iio,Shingo Obika,Masaya Fukushi,Takashi Irie,Daisuke Tsuruta,Shinji Sakamoto,Keiji Tanaka,Yasushi Saeki,Shuya Fukai,Fuminori Tokunaga
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com